Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][6]. Core Viewpoints - The report emphasizes that the Chinese pharmaceutical industry has completed the transition from old to new growth drivers, particularly highlighting the significant potential of innovative drugs. The report suggests that the industry is expected to rebound in the second half of 2025, driven by innovation and the aging population [53][54]. Summary by Sections Industry Performance - From September 22 to September 26, the pharmaceutical index fell by 2.20%, underperforming the CSI 300 index by 3.27%. The report notes a significant adjustment in small-cap stocks since August, but anticipates a stabilization and rebound in innovative drugs due to upcoming catalysts such as ESMO and BD meetings [5][34]. Company Focus: Xinlitai - Xinlitai has made significant strides in its innovative research and development, particularly in the cardiovascular-kidney-metabolism (CKM) chronic disease area. The company has a comprehensive pipeline covering hypertension, dyslipidemia, heart failure, and metabolic diseases, with multiple products already in clinical stages [3][9][15]. - The company’s innovative drug revenue accounted for 58% of its total drug revenue in the first half of 2025, indicating a strong shift towards innovation-driven growth [9][30]. Investment Recommendations - The report recommends focusing on companies that are well-positioned in the innovative drug sector, such as Xinlitai, Healer Pharmaceutical, and others. It also highlights the importance of companies with improving performance and low valuation levels, particularly in the CXO and supply chain sectors [6][53][54]. Market Trends - The report identifies several key trends driving the pharmaceutical industry, including the acceleration of aging demographics, the growth of chronic disease demand, and the increasing importance of innovative drugs in the market. It also notes that the healthcare payment system is evolving to support these trends [53][54]. Performance of Individual Stocks - The report lists top-performing stocks during the week, with Xinlitai showing a 16% increase. Conversely, it notes significant declines in stocks like Borui Pharmaceutical, which fell by 38% [34][36]. Future Outlook - The report anticipates that the pharmaceutical industry will continue to see structural growth, particularly in innovative drugs and medical devices, as well as in the aging population and outpatient consumption sectors. It suggests that companies with strong innovative capabilities and those involved in overseas expansion will be key beneficiaries [53][54].